The abstract is read at the publisher; the summary is JClub's.
Farnesylation-driven KRAS phase separation is linked to advanced colon cancer stages and promotes tumor growth.
- Why it matters: KRAS mutations are common in human cancers, but the mechanisms regulating its activity and contribution to tumor progression remain unclear. Understanding how KRAS functions at the molecular level could reveal new therapeutic targets for colon cancer.
- What they did: The study identified that KRAS forms cytoplasmic condensates via liquid-liquid phase separation driven by farnesylation at residue C185, and screened FDA-approved drugs to find that statins, especially pitavastatin, inhibit this process.
- The result: Disrupting KRAS condensates with statins suppresses colon tumor growth and enhances G12Ci treatment efficacy, suggesting LLPS as a promising target for therapeutic intervention in colon cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.